idarubicin has been researched along with losartan potassium in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chalandon, Y; Helg, C; Stalder, M; Verholen, F | 1 |
| Tohyama, K | 1 |
| Bullova, P; Caisova, V; Gupta, G; Pacak, K; Pang, Y; Schovanek, J; Semenza, GL; Wang, H; Wolf, KI; Yang, C; Zhuang, Z | 1 |
1 review(s) available for idarubicin and losartan potassium
| Article | Year |
|---|---|
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
2 other study(ies) available for idarubicin and losartan potassium
| Article | Year |
|---|---|
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion.
Topics: ABO Blood-Group System; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Group Incompatibility; Blood Transfusion; Combined Modality Therapy; Cytarabine; Drug Resistance; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Killer Cells, Natural; Leukemia, Myelomonocytic, Acute; Leukocyte Transfusion; Male; Middle Aged; Plasmapheresis; Red-Cell Aplasia, Pure; Remission Induction; Rituximab; Transplantation, Homologous | 2004 |
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Growth Processes; Cell Line, Tumor; Endothelin-1; Erythropoietin; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Idarubicin; Mice; Mice, Nude; Neoplasm Metastasis; Pheochromocytoma; Phosphoglycerate Kinase; Protein Binding; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |